Avalo Therapeutics (AVTX) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is AVTX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

WAYNE, Pa., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammat…

Avalo Therapeutics (AVTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings e…

Advancing abdakibart toward a registrational Phase 3 program in hidradenitis suppurativa, with initiation planned for the first half of 2027 Advancing AVTX-010, a next-generation, long-acting anti-IL-1β antibody, toward …

WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammat…

Avalo Therapeutics' positive LOTUS results now support a pivotal trial, and its monthly dosing gives it a potential differentiating factor in HS. Their balance sheet has enough runway to meet their upcoming milestones as…

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.…

Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) hit a new 52-week low on Wednesday. The stock traded as low as $11.99 and last traded at $12.01, with a volume of 1,648,996 shares. The stock had previously close…

WAYNE, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflamma…

WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflamma…

Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) CFO Christopher Sullivan sold 12,394 shares of Avalo Therapeutics stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price…

WAYNE, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflamma…

Avalo Therapeutics (AVTX) is now a well-funded, registrational-stage biotech with validated Phase II data for abdakibart in hidradenitis suppurativa (HS). Abdakibart demonstrated statistically significant HiSCR75 respons…

WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflamma…
Kept in their own lane. A press release is the company talking, not reporting.

